Identification, assessment and reporting of suspected Adverse Drug Reactions (ADRs) to Anti-retroviral therapy (ART) and Anti-tubercular therapy (ATT) in a community care centre at Warangal
Adverse effects of drugs are the main source of morbidity and mortality among the outpatients and inpatients. The objective of the study was to identify, assess and report suspected Adverse Drug Reactions in patients who are diagnosed with Human Immunodeficiency Virus-Acquired Immunodeficiency Syndrome (HIV-AIDS) patients with and without tuberculosis (TB). This was a prospective observational study conducted for a period of six months to explore the significant ADRs caused by Anti-Retroviral and Anti-Tubercular drugs in patients visiting the community care center at Warangal who are diagnosed with HIV-AIDS with or without Tuberculosis as co-infection. In our study, we enrolled 144 patients and a total of 514 ADRs were identified in 125 patients. The most common ADR observed in our study was peripheral neuropathy in 61 patients, followed by vomitings, weakness, anorexia, myalgia, diarrhea, and itching. The ART regimen Stavudine+Lamivudine+Efavirenz (STV+LMV+EFV) was found to be most commonly involved in about 138 ADRs, whereas the regimen Zidovudine+Lamivudine+Nevirapine (ZDV+LMV+NVP) was found to be having the least incidence rate of ADRs. Causality assessment was made using the WHO probability scale and Naranjo’s Scale and 340 (66.14%) and 346 (67.31%) ADRs were classified into Possible respectively. The severity of ADRs were assessed using Hartwig scale and 376 (67.50%) ADRs were classified into Moderate and 138 (26.84%) into Mild ADRs. The findings of our study showed that a huge number of ADRs were experienced by the patients who are receiving ART and ATT which is a major cause for medication Non-compliance and discontinuation of the therapy. Therefore, close monitoring and reporting of ADRs are needed in these patients who are receiving ART and ATT.
2. Kiran L J, Shivashankaramurthy K G, Bhooma S, Dinakar Kr. Adverse drug reaction reporting among clinicians in a teaching hospital in South Karnataka. Scholars Journal of Applied Medical Sciences. 2014;v.2(1):399-403.
3. Miles Hacker, Chapter 13 - Adverse Drug Reactions,Editor(s): Miles Hacker, William Messer, Kenneth Bachmann,Pharmacology,Academic Press.2009; 327-352.
4. Chun TW, Fauci AS. HIV reserviors:Pathogenesis and obstacles to viral eradication and cure. PubMed. 2012;v.26(10):1261-8
5. Wu L Biology of HIV mucosal transmission.PMC.2008;v.3(5):534-540.
6. Gupta K, Klasse PJ.How do viral and host factors modulate the sexual transmission of HIV? Can transmission be blocked?PubMed.2006;v.3(2):e79.
7. Roser m, Ritchie h. HIV/AIDS- OUR WORLD IN DATA [Internet]. OUR WORLD IN DATA. 2018 [cited 5 November 2018]. Available from: https://ourworldindata.org/hiv-aids
8. Trendofnew HIV infections [Internet]. http://aidsinfo.unaids.org/. 2018 [cited 5 November 2018]. Available from: http://aidsinfo.unaids.org/
9. India/data [Internet]. https://data.worldbank.org/country/india. 2018 [cited 5 November 2018]. Available from: https://data.worldbank.org/country/india
10. AIDS 2018 [Internet]. https://www.aids2018.org/. 2018 [cited 5 November 2018]. Available from: https://www.aids2018.org/
11. NACo. (2018). 2017-2018 NACo Annual Report. [online] Available at: https://www.naco.org/annual-report/2017-2018 [Accessed 2 Nov. 2018].
12. Global Tuberculosis Report 2018 [Internet]. http://www.who.int/tb/publications/global_report/en/. 2018 [cited 5 November 2018]. Available from: http://www.who.int/tb/publications/global_report/en/
13. Global Tuberculosis Report 2018 [Internet]. http://www.who.int/tb/publications/global_report/en/. 2018 [cited 5 November 2018]. Available from: http://www.who.int/tb/publications/global_report/en/
14. Martin Vogel, Vogel, Carolynne Schwarze-Zander,Jan-Christian Wasmuth, Ulrich Spengler, Tilman Sauerbruch and Jürgen Kurt Rockstroh.The Treatment of Patients With HIV.PMC.2010;v.107(28-29).
15. How AIDS changed everything [Internet]. .http://www.unaids.org/sites/default/files/media_asset/MDG6Report_en.pdf. 2018[cited5November2018].Available from: .http://www.unaids.org/sites/default/files/media_asset/MDG6Report_en.pdf.
16. Gupta A, Nadkarni G, Yanf WT, Chandrasekhar A, Gupte N, Bisson GP, et al. Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis.PubMed.2011;6:e28691.
17. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. [Internet]. http://www.who.int/hiv/pub/guidelines/arv2013/en/. 2018 [cited 5 November 2018]. Available from: http://www.who.int/hiv/pub/guidelines/arv2013/en/
18. Simona A. Iacob, Diana G. Iacob,and Gheorghita Jugulete.Improving the Adherence to Antiretroviral Therapy, a Difficult but Essential Task for a Successful HIV Treatment—Clinical PointsofViewandPractical Consideration.PMC.2017;v.8:831.
19. den Brinker M, Wit FW, Wertheim-van Dillen PM, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection.PubMed.2000;v.14(18):2895-2902.https://www.ncbi.nlm.nih.gov/pubmed/11153671.
20. Saves M, Raffi F, Clevenbergh P, et al. Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group.PubMed.2000;v.44(12):3451-3455.https://www.ncbi.nlm.nih.gov/pubmed/11083658.
21. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir.PubMed.2008;v.358(6):568-579.https://www.ncbi.nlm.nih.gov/pubmed/18256392.
22. Saag M, Balu R, Phillips E, et al. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients.PubMed.2008;v.46(7):1111-1118.https://www.ncbi.nlm.nih.gov/pubmed/18444831.
23. Sujit Suchindran, Emily S Brouwer, Annelies Van Rie.Is HIV Infection a Risk Factor for Multi-Drug Resistant Tuberculosis? A Systematic Review.Plos One.2009;0005561
24. Rajesh R, Vidyasagar S,Nandakumar K,et al. Highly active AntiRetroviral therapy induced ADR in Indian HIV positive patients.Pubmed.2011;v.9(1):48-55
25. Fithamlak S, Banchalem A, Hailu K, Efrata T, Tezera B, Mahlet A, et al. Spectrum of opportunistic infections and associated factors among people living with HIV/AIDS in the era of highly active anti-retroviral treatment in Dawro Zone hospital: a retrospective study.PMC.2018;v.11:604
26. Debasu D, Gizacgew Y, Desalegn W, Belay A, et al. Common opportunistic infections and their CD4 cell correlates among HIV infected patients attending at antiretroviral therapy clinic of Gondar University Hospital, Northwest Ethiopia.PMC.2013;v.6:534
27. B Akshaya S, Chandra B, Harlokesh Y, Sunil K, et al. Incidence of adverse drug reactions in human deficiency virus positive patients using highly active retroviral therapy.PMC.2012;v.3(1):62-67
28. Menezes de pauda, C.C.Cesar, P.F. Bonolo, F.A.Acurcio, M.D.C.Guimaraes et al. High incidence of adverse reactions to initial antiretroviral therapy in Brazil.Braz J Med Bio Res.2006;v.39,495-505
29. Breen RA, Miller RF, Gorsuch T, Smith CJ, Schwenk A, Holmes W, Ballinger J, Swaden L, Johnson MA, Cropley I, Lipman MC. Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection.PubMed.2006;v.61(9):791-4
Copyright © Author(s) retain the copyright of this article.